← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 Pacific Biosciences PACB $609M	90	-12	-12%	$156M
27	BLCM 27 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	83	+2	+2%	$230M
28	28 Invesco Biotechnology & Genome ETF PBE $429M	82	-4	-5%	$133M
29	29 Lineage Cell Therapeutics LCTX $250M	74	-6	-8%	$98.6M
30	SIOX 30 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	71	+19	+37%	$1.29B
31	NSTG 31 DELISTED NanoString Technologies, Inc. NSTG	62	0	0%	$245M
32	32 uniQure QURE $1.56B	62	+9	+17%	$162M
33	33 Veracyte VCYT $3.57B	61	+1	+2%	$73.5M
34	AGTC 34 DELISTED Applied Genetic Technologies Corporation AGTC	60	-3	-5%	$121M
35	35 Arbutus Biopharma ABUS $850M	55	-8	-13%	$212M
36	36 Rocket Pharmaceuticals RCKT $259M	53	+34	+179%	$175M
37	NVTA 37 DELISTED Invitae Corporation NVTA	50	-5	-9%	$141M
38	38 Regenxbio RGNX $473M	48	+48	–	$310M
39	39 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	47	-19	-29%	$9.59M
40	ATHX 40 DELISTED Athersys, Inc. Common Stock ATHX	46	+5	+12%	$8.16M
41	41 Fate Therapeutics FATE $231M	44	+5	+13%	$97.8M
42	42 Abeona Therapeutics ABEO $266M	43	+1	+2%	$30.1M
43	43 Cellectis CLLS $111M	43	+3	+8%	$181M
44	ADAP 44 DELISTED Adaptimmune Therapeutics ADAP	41	-4	-9%	$181M
45	45 Fortress Biotech FBIO $63.7M	39	-2	-5%	$18.6M
46	46 Lakefront Biotherapeutics American Depositary Shares LKFT $1.96B	38	-3	-7%	$368M
47	47 ProQR Therapeutics PRQR $205M	37	0	0%	$162M
48	48 Vericel Corp VCEL $2.1B	37	-1	-3%	$28.7M
49	49 Neurogene NGNE $479M	33	+6	+22%	$183M
50	50 Opus Genetics IRD $337M	31	-4	-11%	$4.56M